Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Biocompatibility studies of fluorescent diamond particles-(NV)~800nm (part V): in vitro kinetics and in vivo localization in rat liver following long-term exposure.

Gerstenhaber JA, Marcinkiewicz C, Barone FC, Sternberg M, D'Andrea MR, Lelkes PI, Feuerstein GZ.

Int J Nanomedicine. 2019 Aug 12;14:6451-6464. doi: 10.2147/IJN.S209663. eCollection 2019.

2.

Rosiglitazone treatment restores renal responsiveness to atrial natriuretic peptide in rats with congestive heart failure.

Goltsman I, Khoury EE, Aronson D, Nativ O, Feuerstein GZ, Winaver J, Abassi Z.

J Cell Mol Med. 2019 Jul;23(7):4779-4794. doi: 10.1111/jcmm.14366. Epub 2019 May 13.

3.

Long-term biocompatibility of fluorescent diamonds-(NV)-Z~800 nm in rats: survival, morbidity, histopathology, particle distribution and excretion studies (part IV).

Barone FC, Marcinkiewicz C, Li J, Feng Y, Sternberg M, Lelkes PI, Rosenbaum-Halevi D, Gerstenhaber JA, Feuerstein GZ.

Int J Nanomedicine. 2019 Feb 14;14:1163-1175. doi: 10.2147/IJN.S189048. eCollection 2019.

4.

Pharmacology in cerebrovascular disease research: Pharmacokinetics-pharmacodynamics to the rescue.

Feuerstein GZ.

J Cereb Blood Flow Metab. 2016 Mar;36(3):639-44. doi: 10.1177/0271678X15619429. Epub 2015 Nov 30.

5.

Potential early predictors for outcomes of experimental hemorrhagic shock induced by uncontrolled internal bleeding in rats.

Abassi ZA, Okun-Gurevich M, Abu Salah N, Awad H, Mandel Y, Campino G, Mahajna A, Feuerstein GZ, Fitzpatrick M, Hoffman A, Winaver J.

PLoS One. 2013 Nov 26;8(11):e80862. doi: 10.1371/journal.pone.0080862. eCollection 2013.

6.

Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans.

Japp AG, Chelliah R, Tattersall L, Lang NN, Meng X, Weisel K, Katz A, Burt D, Fox KA, Feuerstein GZ, Connolly TM, Newby DE.

J Am Heart Assoc. 2013 Jan 28;2(1):e006007. doi: 10.1161/JAHA.112.006007.

7.

In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans.

Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, Gray C, Crawford JH, Alam SR, Atkinson AP, Forrest EK, Bienek C, Mills NL, Burdess A, Dhaliwal K, Simpson AJ, Wallace WA, Hill AT, Roddie PH, McKillop G, Connolly TA, Feuerstein GZ, Barclay GR, Turner ML, Newby DE.

Circ Cardiovasc Imaging. 2012 Jul;5(4):509-17. doi: 10.1161/CIRCIMAGING.112.972596. Epub 2012 Jul 10.

PMID:
22787016
8.

In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant Pseudomonas aeruginosa.

Adawi A, Bisignano C, Genovese T, Filocamo A, Khouri-Assi C, Neville A, Feuerstein GZ, Cuzzocrea S, Neville LF.

Int J Mol Med. 2012 Sep;30(3):455-64. doi: 10.3892/ijmm.2012.1040. Epub 2012 Jun 20.

9.

Lyophilised reconstituted human platelets increase thrombus formation in a clinical ex vivo model of deep arterial injury.

Joshi NV, Raftis JB, Lucking AJ, Hunter AH, Millar M, Fitzpatrick M, Feuerstein GZ, Newby DE.

Thromb Haemost. 2012 Jul;108(1):176-82. doi: 10.1160/TH12-02-0059. Epub 2012 May 25.

PMID:
22627761
10.

Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.

Wang X, Zhan Y, Zhao L, Alvarez J, Chaudhary I, Zhou BB, Abraham RT, Feuerstein GZ.

J Pharmacol Exp Ther. 2011 Nov;339(2):421-9. doi: 10.1124/jpet.111.185249. Epub 2011 Aug 11.

PMID:
21835932
11.

Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure.

Goltsman I, Wang X, Lavallie ER, Diblasio-Smith EA, Ovcharenko E, Hoffman A, Abassi Z, Feuerstein GZ, Winaver J.

Circ Heart Fail. 2011 May;4(3):345-54. doi: 10.1161/CIRCHEARTFAILURE.110.960179. Epub 2011 Mar 11.

PMID:
21398416
12.

Characterisation and reproducibility of a human ex vivo model of thrombosis.

Lucking AJ, Chelliah R, Trotman AD, Connolly TM, Feuerstein GZ, Fox KA, Boon NA, Badimon JJ, Newby DE.

Thromb Res. 2010 Nov;126(5):431-5. doi: 10.1016/j.thromres.2010.06.030. Epub 2010 Aug 25.

PMID:
20800267
13.

Generation, validation and humanisation of a novel insulin resistant cell model.

Logie L, Ruiz-Alcaraz AJ, Schofield CJ, Hundal HS, Feuerstein GZ, Brady JD, Crowther D, Tommasi AM, Grierson CE, Shepherd B, Morris AD, Hansen MK, Pearson E, Sutherland C.

Biochem Pharmacol. 2010 Oct 1;80(7):1042-9. doi: 10.1016/j.bcp.2010.06.011. Epub 2010 Jun 23.

PMID:
20599791
14.

Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.

Wang X, Liu X, Zhan Y, Lavallie ER, Diblasio-Smith L, Collins-Racie L, Mounts WM, Rutkowski JL, Xu X, Goltsman I, Abassi Z, Winaver J, Feuerstein GZ.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):820-9. doi: 10.1124/jpet.110.167635. Epub 2010 Jun 2.

PMID:
20519551
15.

Peroxisome proliferator-activated receptor alpha and alpha/gamma agonists do not cause impairment in renal function in the rat.

Ovcharenko E, Hansen MK, Goltsman I, Abu-Saleh N, Abassi Z, Walsh K, Miele G, Feuerstein GZ, Winaver J.

Nephron Physiol. 2010;115(3):p21-30. doi: 10.1159/000314541. Epub 2010 May 12.

PMID:
20460939
16.

Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.

Wan HI, Jacobsen JS, Rutkowski JL, Feuerstein GZ.

Clin Transl Sci. 2009 Jun;2(3):242-7. doi: 10.1111/j.1752-8062.2009.00121.x. No abstract available.

17.
18.

Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis.

Lucking AJ, Visvanathan A, Philippou H, Fraser S, Grant PJ, Connolly TM, Gardell SJ, Feuerstein GZ, Fox KA, Booth NA, Newby DE.

J Thromb Haemost. 2010 Jun;8(6):1333-9. doi: 10.1111/j.1538-7836.2010.03872.x. Epub 2010 Mar 25.

19.

Translational medicine--a paradigm shift in modern drug discovery and development: the role of biomarkers.

Day M, Rutkowski JL, Feuerstein GZ.

Adv Exp Med Biol. 2009;655:1-12. doi: 10.1007/978-1-4419-1132-2_1. Review.

PMID:
20047030
20.

Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch.

Chavez JC, Hurko O, Barone FC, Feuerstein GZ.

Stroke. 2009 Oct;40(10):e558-63. doi: 10.1161/STROKEAHA.109.559914. Epub 2009 Sep 10. Review.

PMID:
19745180
21.

P-selectin antagonism reduces thrombus formation in humans.

Chelliah R, Lucking AJ, Tattersall L, Daga S, Beresford-Cleary NJ, Cortas K, Fox KA, Feuerstein GZ, Connolly TM, Newby DE.

J Thromb Haemost. 2009 Nov;7(11):1915-9. doi: 10.1111/j.1538-7836.2009.03587.x. Epub 2009 Aug 19.

22.

The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.

Abassi Z, Winaver J, Feuerstein GZ.

Biochem Pharmacol. 2009 Oct 15;78(8):933-40. doi: 10.1016/j.bcp.2009.05.018. Epub 2009 May 27. Review.

PMID:
19477166
23.

Translational medicine for stroke drug discovery: the pharmaceutical industry perspective.

Feuerstein GZ, Chavez J.

Stroke. 2009 Mar;40(3 Suppl):S121-5. doi: 10.1161/STROKEAHA.108.535104. Epub 2008 Dec 8.

PMID:
19064772
24.

The development of stroke therapeutics: promising mechanisms and translational challenges.

Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN, Wood A.

Neuropharmacology. 2009 Feb;56(2):329-41. doi: 10.1016/j.neuropharm.2008.10.006. Epub 2008 Nov 1. Review.

PMID:
19007799
25.

Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk.

Wang X, Keith JC Jr, Struthers AD, Feuerstein GZ.

Cardiovasc Ther. 2008 Fall;26(3):214-23. doi: 10.1111/j.1755-5922.2008.00051.x. Review.

PMID:
18786091
26.

Multimodal magnetic resonance imaging for assessing evolution of ischemic penumbra: a key translational medicine strategy to manage the risk of developing novel therapies for acute ischemic stroke.

Chavez JC, Zaleska MM, Wang X, Wood A, Hurko O, Pangalos MN, Feuerstein GZ.

J Cereb Blood Flow Metab. 2009 Jan;29(1):217-9. doi: 10.1038/jcbfm.2008.103. Epub 2008 Sep 3.

PMID:
18766199
27.

Cardiac RAGE in sepsis: call TOLL free for anti-RAGE.

Feuerstein GZ.

Circ Res. 2008 May 23;102(10):1153-4. doi: 10.1161/CIRCRESAHA.108.177261. No abstract available.

PMID:
18497315
28.

Fifty years of Biochemical Pharmacology: the discipline and the journal.

Enna SJ, Feuerstein GZ, Piette J, Williams M.

Biochem Pharmacol. 2008 Jul 1;76(1):1-10. doi: 10.1016/j.bcp.2008.03.024. Epub 2008 Apr 11.

PMID:
18485330
29.

Role of chemokines in atherosclerosis.

Feuerstein GZ, Wang X.

IDrugs. 1998 Aug;1(4):424-8.

PMID:
18465575
30.

Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics.

Sellar G, Alvarez JD, Loganzo F, Abbas R, Immermann F, Karnoub M, Feuerstein GZ, Burczynski ME, Coughlin CM.

Biomark Med. 2008 Apr;2(2):147-53. doi: 10.2217/17520363.2.2.147.

PMID:
20477436
31.

Discontinued drugs in 2006: cardiovascular drugs translational medicine perspective.

Feuerstein GZ, Ruffolo RR.

Expert Opin Investig Drugs. 2007 Sep;16(9):1315-26. Review.

PMID:
17714019
32.

The effect of diet on simvastatin and losartan enhancement of endothelial function.

Bayorh MA, Layas MF, Mann G, Feuerstein GZ, Eatman D.

Clin Exp Hypertens. 2007 Jul;29(5):311-25.

PMID:
17653966
33.

Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.

Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, Finklestein SP, Pangalos MN, Poole M, Stiles GL, Ruffolo RR, Walsh FL.

J Cereb Blood Flow Metab. 2008 Jan;28(1):217-9. Epub 2007 Jun 20. Review.

PMID:
17579658
34.

Imaging and molecular biomarkers of vulnerable atheromatous plaques.

Wang X, Rutkowsky JL, Feuerstein GZ.

Biomark Med. 2007 Jun;1(1):23-35. doi: 10.2217/17520363.1.1.23.

PMID:
20477458
35.

Identification and characterization of triosephosphate isomerase that specifically interacts with the integrin alphaIIb cytoplasmic domain.

Liu QY, Corjay M, Feuerstein GZ, Nambi P.

Biochem Pharmacol. 2006 Aug 28;72(5):551-7. Epub 2006 Jul 20.

PMID:
16859644
36.

Translational stroke research in the developing brain.

Vexler ZS, Sharp FR, Feuerstein GZ, Ashwal S, Thoresen M, Yager JY, Ferriero DM.

Pediatr Neurol. 2006 Jun;34(6):459-63.

PMID:
16765824
37.

Carvedilol case history: the discovery and development of the first β-blocker for the treatment of congestive heart failure.

Ruffolo RR, Feuerstein GZ.

Expert Opin Drug Discov. 2006 Jun;1(1):85-9. doi: 10.1517/17460441.1.1.85.

PMID:
23506034
38.

Neuropeptide Y and the heart: implication for myocardial infarction and heart failure.

Feuerstein GZ, Lee EW.

EXS. 2006;(95):113-22. Review. No abstract available.

PMID:
16383001
39.

Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.

Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ.

Am J Hypertens. 2005 Nov;18(11):1496-502.

PMID:
16280288
40.
41.

Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.

Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D.

J Thromb Haemost. 2005 Apr;3(4):695-702. Epub 2005 Feb 23.

42.

Pharmaceutical biotechnology.

Guzman CA, Feuerstein GZ.

Curr Opin Biotechnol. 2004 Dec;15(6):503-5. No abstract available.

PMID:
15560975
43.

The Janus face of inflammation in ischemic brain injury.

Wang X, Feuerstein GZ.

Acta Neurochir Suppl. 2004;89:49-54. Review.

PMID:
15335100
44.

Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats.

Wang X, Feuerstein GZ, Xu L, Wang H, Schumacher WA, Ogletree ML, Taub R, Duan JJ, Decicco CP, Liu RQ.

Mol Pharmacol. 2004 Apr;65(4):890-6.

PMID:
15044618
45.

Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury.

Wang X, Li X, Xu L, Zhan Y, Yaish-Ohad S, Erhardt JA, Barone FC, Feuerstein GZ.

Mol Pharmacol. 2003 Oct;64(4):833-40.

PMID:
14500739
46.

Role of immune and inflammatory mediators in CNS injury.

Wang X, Feuerstein GZ.

Drug News Perspect. 2000 Apr;13(3):133-40.

PMID:
12937603
47.

Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro.

Racanelli AL, Gibbs SK, Zondlo SC, Seiffert DA, Friedman SM, Feuerstein GZ.

Thromb Res. 2003 May 1;110(2-3):99-105.

PMID:
12893024
48.
49.

Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats.

Wang X, Xu L, Wang H, Grzanna R, Zhan Y, Knabb RM, Luettgen JM, Bozarth TA, Galemmo RA, Wong PC, Bernard R, Vargas H, Chopp M, Friedman SM, Feuerstein GZ.

Stroke. 2003 Feb;34(2):468-74.

PMID:
12574562
50.

Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis.

Wang X, Wang H, Xu L, Rozanski DJ, Sugawara T, Chan PH, Trzaskos JM, Feuerstein GZ.

J Pharmacol Exp Ther. 2003 Jan;304(1):172-8.

PMID:
12490588

Supplemental Content

Loading ...
Support Center